IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers

Chimeric antigen receptor (CAR)-T cell-based therapies demonstrate remarkable efficacy for the treatment of otherwise intractable cancers, particularly B-cell malignancies. However, existing FDA-approved CAR-Ts are limited by low antigen sensitivity, rendering their insufficient targeting to low ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinyan, Xiao, Qian, Zeng, Longhui, Hashmi, Fawzaan, Su, Xiaolei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592880/
https://www.ncbi.nlm.nih.gov/pubmed/37873222
http://dx.doi.org/10.1101/2023.10.02.560460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592880/
https://www.ncbi.nlm.nih.gov/pubmed/37873222
http://dx.doi.org/10.1101/2023.10.02.560460

Ejemplares similares